Cynosure Group’s PTC Therapeutics PTCT Stock Holding History

Cynosure Group’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,728	Closed	-$458K	–	240
2026 Q1	$458K	Buy	+6,728	New	+$476K	0.06%	95

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Cynosure Group's PTCT Position: Q2 2026 in Review

Cynosure Group sold out of PTC Therapeutics (PTCT) in Q2 2026, closing a stake of 6,728 shares — an estimated $458K sold.

Cynosure Group first reported a position in PTCT in Q1 2026 and held it in 1 quarter. The position peaked at $458K in Q1 2026. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Cynosure Group reported no remaining PTC Therapeutics position as of Q2 2026 after selling out during the quarter.
Cynosure Group sold 6,728 PTC Therapeutics shares in Q2 2026, an estimated $458K.
Cynosure Group first reported a position in PTC Therapeutics in Q1 2026 and held it in 1 quarter.
Cynosure Group's PTC Therapeutics position peaked at $458K in Q1 2026.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Cynosure Group's 13F filing for Q2 2026, filed 5 Aug 2026.